Digestive Diseases and Sciences

, Volume 55, Issue 7, pp 2086–2088 | Cite as

Statins in Primary Biliary Cirrhosis: Are They Safe?

  • Murad Abu Rajab
  • Marshall M. Kaplan
Original Article


Background and Aim

Although cholesterol levels are elevated in patients with primary biliary cirrhosis (PBC), most PBC patients are not at increased risk of dying from atherosclerotic heart disease. There is, however, a subgroup, approximately 10%, who have additional disorders of lipid metabolism. They might benefit from a cholesterol-lowering agent. However, there is concern about using statins in patients with pre-existing liver disease. We therefore reviewed our experience with statins in a large cohort of PBC patients who were seen at Tufts Medical Center during the past decade.


From January 1, 1996, until June 30, 2006, 603 patients with PBC were seen by one of us (M.M.K.). Fifty-eight were on statins and five were on ezetimibe. The mean duration of usage was 41 months (range 3–125 months). Alanine aminotransferase (ALT) levels were measured at 3-month intervals.


Statins were well tolerated. No patient complained of muscle pain or weakness. There was no increase in ALT levels. ALT levels were slightly elevated at the time that statins were begun (41.7 ± 25.1 U/l), and were normal at the last time these patients were seen (39.0 ± 21.0 U/l) (P ≤ 0.303). Serum cholesterol levels decreased by 30%, from 262 ± 45 mg/dl to 181 ± 14 mg/dl (P < 0.01). Ezetimibe was also well tolerated.


Statins are safe in PBC patients who might benefit from their use.


Primary biliary cirrhosis Statins Hepatotoxicity 


  1. 1.
    Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261–1273.CrossRefPubMedGoogle Scholar
  2. 2.
    Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51:265–269.CrossRefPubMedGoogle Scholar
  3. 3.
    Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287–1292.CrossRefPubMedGoogle Scholar
  4. 4.
    Vuppalanchi R, Chalasani N. Statins for hyperlipidemia in patients with chronic liver disease: are they safe? Clin Gastroenterol Hepatol. 2006;4:838–839.CrossRefPubMedGoogle Scholar
  5. 5.
    Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol. 2006;4:902–907.CrossRefPubMedGoogle Scholar
  6. 6.
    Stanca CM, Bach N, Allina J, Bodian C, Bodenheimer H Jr, Odin JA. Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis. Dig Dis Sci. 2008;53:1988–1993.CrossRefPubMedGoogle Scholar
  7. 7.
    Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology. 2007;46:776–784.CrossRefPubMedGoogle Scholar
  8. 8.
    Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW, Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol. 2002;36:454–458.CrossRefPubMedGoogle Scholar
  9. 9.
    Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453–1463.CrossRefPubMedGoogle Scholar
  10. 10.
    Tuteja S, Pyrsopoulos NT, Wolowich WR, et al. Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. Pharmacotherapy. 2008;28:1188–1193.CrossRefPubMedGoogle Scholar
  11. 11.
    Jahn CE, Schaefer EJ, Taam LA, et al. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology. 1985;89:1266–1278.PubMedGoogle Scholar
  12. 12.
    Grundy SM, Vega GL, Garg A. Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in various forms of dyslipidemia. Am J Cardiol. 1990;66:31B–38B.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of Gastroenterology, Department of MedicineTufts Medical CenterBostonUSA

Personalised recommendations